OBJECTIVE: Type 2 @entity6 may be present for several years before diagnosis, by which time many @entity1 have already developed @entity6 complications. Earlier detection and treatment may reduce this burden, but evidence to support this approach is lacking. RESEARCH DESIGN AND METHODS: Glycemic control and clinical and surrogate outcomes were compared for 5,088 of 5,102 U.K. @entity6 Prospective Study @entity1 according to whether they had low (<140 mg/dl [<7.8 mmol/l]), intermediate (140 to <180 mg/dl [7.8 to <10.0 mmol/l]), or high (> or =180 mg/dl [> or =10 mmol/l]) fasting plasma @entity413 (FPG) levels at diagnosis. Individuals who presented with and without @entity6 symptoms were also compared. RESULTS: Fewer @entity1 with FPG in the lowest category had @entity989 , abnormal biothesiometer measurements, or reported @entity323 . The rate of increase in FPG and HbA(1c) during the study was identical in all three groups, although absolute differences persisted. Individuals in the low FPG group had a significantly reduced risk for each predefined clinical outcome except @entity64 , whereas those in the intermediate group had significantly reduced risk for each outcome except @entity64 and @entity583 . The low and intermediate FPG groups had a significantly reduced risk for progression of @entity989 , @entity10795 sensory threshold, or development of microalbuminuria. CONCLUSIONS: @entity1 presenting with @entity164 2 @entity6 with lower initial glycemia who may be earlier in the course of their disease had fewer adverse clinical outcomes despite similar glycemic progression. Since most such @entity1 are asymptomatic at diagnosis, active case detection programs would be required to identify them.

Are lower fasting plasma @entity413 levels at diagnosis of @entity164 2 @entity6 associated with improved outcomes?: U.K. prospective XXXX study 61.

@entity1 :: ('9606', 'Species') :: ['participants', 'patients', 'people', 'People'] @entity323 :: ('MESH:D007172', 'Disease') :: ['erectile dysfunction'] @entity64 :: ('MESH:D020521', 'Disease') :: ['stroke'] @entity6 :: ('MESH:D003920', 'Disease') :: ['Diabetes', 'diabetic', 'diabetes'] @entity10795 :: ('MESH:D053421', 'Disease') :: ['reduction in vibration'] @entity164 :: ('MESH:D017827', 'Disease') :: ['type'] @entity989 :: ('MESH:D012164', 'Disease') :: ['retinopathy'] @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']
@entity6 :: (MESH:D003920,Disease) :: ['diabetes']
